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Results of Lung Cancer Screening in the Community
ABSTRACT
PURPOSE To address doubts regarding National Lung Screening Trial (NLST) 
generalizability, we analyzed over 6,000 lung cancer screenings (LCSs) within a 
community health system.
METHODS Our LCS program included 10 sites, 7 hospitals (2 non-university tertiary 
care, 5 community) and 3 free-standing imaging centers. Primary care clinicians 
referred patients. Standard criteria determined eligibility. Dedicated radiologists 
interpreted all LCSs, assigning Lung Imaging Reporting and Data System (Lung-
RADS) categories. All category 4 Lung-RADS scans underwent multidisciplinary 
review and management recommendations. Data was prospectively collected 
from November 2013 through December 2018 and retrospectively analyzed.
RESULTS Of 4,666 referrals, 1,264 individuals were excluded or declined, and 
3,402 individuals underwent initial LCS. Second through eighth LCSs were per-
formed on 2,758 patients, for a total of 6,161 LCSs. Intervention rate after LCS 
was 14.6% (500 individuals) and was most often additional imaging. Invasive 
interventions (n = 226) were performed, including 141 diagnostic procedures and 
85 surgeries in 176 individuals (procedure rate 6.6%). Ninety-five lung cancers 
were diagnosed: 84 non-small cell (stage 1: 60; stage 2: 7; stage 3: 9; stage 4: 
8), and 11 small cell lung cancers. The procedural adverse event rate was 23/226 
(10.1%) in 21 patients (0.6% of all screened individuals). Pneumothorax (n = 10) 
was the most frequent, 6 requiring pleural drainage. There were 2 deaths among 
85 surgeries or 2.3% surgical mortality.
CONCLUSIONS Our LCS experience in a community setting demonstrated lung 
cancer diagnosis, stage shift, intervention frequency, and adverse event rate 
similar to the NLST. This study confirms that LCS can be performed successfully, 
safely, and with equivalence to the NLST in a community health care setting.
Ann Fam Med 2020;18:243-249. https://doi.org/10.1370/afm.2519.
INTRODUCTION
Since 2011, when the National Lung Screening Trial (NLST) results showed a 20% decrease in lung cancer–specific mortality in a high risk population,1 lung cancer screening (LCS), using low-dose com-
puted tomography, has been recommended as the standard of care by 
most professional and patient advocacy organizations.2-5 Guidelines for 
LCS programs have been published6,7 and LCS implementation has been 
described.8 The NLST listed as one of the study weaknesses the recog-
nized expertise of the participating medical centers “in radiology and in 
the diagnosis and treatment of cancer” which raised the question of the 
generalizability of their results to community facilities.1 This concern was 
amplified by the American Academy of Family Physicians and contributed 
to the organization not endorsing LCS.9,10 To evaluate these concerns, we 
aim to describe our LCS program experience within a large metropolitan 
non-university, non-NLST, community, tertiary care system.
METHODS
Providence St Joseph Health (PSJH) system is one of the largest inte-
grated systems in the United States and includes multiple outpatient care 
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facilities, an insurance product, and 50 hospitals in 
Alaska, California, Montana, New Mexico, Oregon, 
Texas, and Washington. Integrated systems have inter-
nal operational accountability, allowing for comprehen-
sive review of clinical care. Our LCS program operated 
in the Portland, Oregon region of the PSJH system. 
The program was implemented by the cancer services 
group rather than the diagnostic imaging group due to 
clinical leadership, program novelty, and lack of a tem-
plate. The LSC program began operations in Novem-
ber 2013 incorporating 7 hospitals (2 non-university 
tertiary and 5 community medical centers) and 3 free-
standing imaging centers, in coordination with our 
interdisciplinary thoracic oncology program.
Patients were referred by primary care clinicians 
within and outside of PSJH. The program process is 
illustrated in Figure 1. Initially, shared decision making 
was provided by the LCS team, but in 2015, this tran-
sitioned to the primary care clinicians at their request 
due to their established patient-clincian relationship 
leveraging more intimate knowledge of patient-specific 
values in shared decision making. Lung cancer screen-
ing was carried out using NLST eligibility criteria, 
and after February 2015, the Centers for Medicare & 
Medicaid Services eligibility criteria (age 55-77 years, 
at least 30 packs per year smoking, smoking cessation 
less than 15 years, no cancer symptoms, no concomi-
tant life threatening illness, medically fit and willing 
to undergo additional indicated medical management 
and future LCS).11 Patients not meeting eligibility were 
not screened. The required program components6,7 
of smoking cessation and patient education were pro-
vided by the program coordinator, and after 2015, by 
primary care clinicians. Additional patient and clinician 
education was provided by a website12 that incorpo-
rated risk calculators and shared decision making tools. 
Primary care clinicians employed by PSJH ordered 
LCS via the electronic health record after eligibility 
determination and shared decision making. Non-PSJH 
clinicians faxed standardized order forms. A second 
eligibility check was carried out by a coordinator or 
by a diagnostic radiology team member before the 
scan. Lung cancer screening was carried out annually.2 
Automated notification of follow-up LCS and patient 
reminder letters were initiated in 2017.
All LCS examination techniques were standard-
ized and performed in accordance with the American 
College of Radiology standard protocol specifying 
acceptable characteristics of the imaging machine and 
acquisition variables.6,7 Designated radiologists at the 
tertiary centers interpreted all the LCS results using 
algorithms for lung nodule identification and imaged 
lung nodule management. Interpretation utilized 
structured reporting, interpreting via an internally 
designed system (normal, suspicious-probably benign, 
suspicious-probably malignant, incidental finding-
urgent/non-urgent). In 2014, this system was replaced 
by the Lung Imaging Reporting and Data System 
(Lung-RADS) categories. Briefly, Lung-RADS 1, 2, and 
3 are negative (no nodules), benign, and probably benign, 
respectively. Category 4 is suspicious, requires further 
evaluation, and carries a ≥15% probability of malig-
nancy.13 Every Lung-RADS 4 LCS result underwent 
Figure 1. Lung cancer screening process.
CT = computed tomography; LCS = lung cancer screening; lung-RADS = Lung 
Imaging Reporting and Data System; PCC = primary care clinician; 
SDM = shared decision making.
LCS process
PCC maintains primary patient care role
Program works with PCC to schedule 
follow-up scans if needed
If lung cancer suspected, patient 
scheduled with thoracic specialists
All lung-RADs 4 scans reviewed 
at Providence Multidisciplinary 
Thoracic Disease Conference
Thoracic radiologist reviews scans and 
reports  ndings to PCC and patient
Screening chest CT (0.8-1.5 mSv)
Diagnostic imaging schedules 
screening CT with patient
PCC orders CT screening
Shared decision making:
1. Smoking cessation intervention
2. Review bene ts & risks of screening
3. Personalize decision with SDM tool
PCC & patient: shared decision
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review by a multidisciplinary thoracic disease confer-
ence (MTDC) consisting of physicians from pulmon-
ology, thoracic surgery, medical oncology, radiation 
oncology, thoracic pathology, and thoracic radiology 
services. The MTDC generated guideline-compliant 
management recommendations to the referring pri-
mary care clinician, but where ambiguous, with an 
intentional program bias towards minimizing interven-
tions. The primary care clinician managed all subse-
quent activity until referral to specialists.
Physicians involved in the program were from sev-
eral medical settings, including some PSJH-employed 
groups (medical oncology, pathology, and thoracic 
surgery) and some fee-for-service groups (radiology, 
pulmonology, radiation oncology, and thoracic sur-
gery). A PSJH full-time employee program coordina-
tor recorded all imaging, procedures, adverse events, 
pathology, staging, and ensured follow-up LCS. The 
coordinator utilized a clinical research database that 
included registration (demographics, smoking history), 
schedule (all screening computed tomography scans, 
next due date), and post visit (scan information, LCS-
generated procedures, or cancer diagnosis). Monthly, 
the coordinator generated a list of patients due for 
LCS. Each patient was sent 3 reminder letters. The 
referring clinician was notified that the patient was 
due for follow-up scan. The coordinator tracked the 
patients undergoing (or declining) LCS.
In 2014, our program was designated a Screening 
Center of Excellence by the Lung Cancer Alliance 
patient advocacy group.14
We retrospectively analyzed prospectively col-
lected clinical data on individuals referred to our LCS 
program. Data was collected over 62 months (Novem-
ber 2013-December 2018) and analyzed. This study 
was approved by the Institutional Review Board (IRB 
2018000035).
RESULTS
Of 4,666 referrals, 1,264 individuals were 
excluded or declined, and 3,402 individuals 
underwent initial LCS. Approximately 30% 
of LCS referrals originated from outside 
PSJH. Three of 3,402 LCS individuals were 
lost to follow-up (0.08%). Second through 
eighth LCSs were performed on 2,758 
patients, for a total of 6,161 LCSs. Table 1 
displays demographic information on the 
2,513 people enrolled in the program at 
time of data review. The baseline scan total 
of 3,402 individuals was an accumulation of 
LCSs since 2013. At the time of data cap-
ture some of these patients had completed 
the program or had declined further participation, 
and they are not represented in Table 1. The details 
of LCSs after the initial screening is shown in Table 
2. Figure 2 displays our LCS volume over the study 
period. Lung cancer screening Lung-RADs 4 presenta-
tions to the MTDC were not tracked until late 2015 
and numbered: 48 in 2015, 94 in 2016, 92 in 2017, and 
122 in 2018 for a total of 356.
Of the entire screened population, 500 patients 
(14.6%) had a result that triggered further investigation 
at some point during screening. Of those, 324 under-
went additional imaging only. Table 3 depicts imaging 
activity in all patients requiring additional investiga-
tion (imaging and/or invasive procedures), with 31% 
performed outside of PSJH. There were 226 invasive 
Table 1. Demographics of Enrolled Lung Cancer 











African American 33 (1)
Other 72 (3)
American Indian or Alaska native 15 (<1)





Table 2. Subsequent Patient Screening After Initial LCS 
(N = 3,402)
Activity Type No. (%)
Enrolled or completed LCS program during study period 2,791 (82)
Did not schedule or declined PCC-ordered LSC 258 (8)
Had diagnostic CTs (from LCS & not from LCS) 79 (2)
Subsequent LCS scans outside PSJH 61 (2)
Initial LCS resulted in diagnosis of cancer, no other LCS 51 (2)
Had repeat scans within PSJH but after end of study period 50 (1)
Changed insurance, other insurance issue, changed PCC, or 
had no PCC
46 (1)
PCC declined or did not send subsequent orders 43 (1)
Moved 23 (1)
CT = computed tomography; LCS = lung cancer screening; PCC = primary care clinician; 
PSJH = Providence St Joseph Health.
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procedures were performed in 176 patients, with 
or without imaging (Table 4), with 17% performed 
outside PSJH. Invasive diagnostic procedures were 
performed in 121 patients, the majority being bron-
choscopy. Surgery was performed in 81 patients, the 
majority for a diagnosed malignancy (thoracic or extra-
thoracic). Among 56 pulmonary resections for antici-
pated malignancy, 7 (12%) ultimately proved to be 
benign. None of the 7 patients experienced an adverse 
event. All lung resections were thoracoscopic.
A total of 111 malignancies were diagnosed in 
3,402 screened individuals. There were 95 lung can-
cers detected and 16 other malignancies (Table 5). Of 
note, early stage non-small cell cancer was detected in 
67 patients (70% of diagnosed lung cancer) where sur-
gical resection is the preferred treatment. Among early 
clinical stage lung cancer patients, 25 did not undergo 
resection: 1 refused any further evaluation, 18 were 
poor surgical candidates and underwent ablative radia-
tion, 6 refused surgery, opting for ablative radiation. 
Of lung cancers diagnosed, 49% were detected on the 
initial LCS and the remaining 51% were detected dur-
ing follow-up LCS.
Table 6 shows 23 procedure-related adverse events 
in 21 patients (0.6% of screened population), including 2 
deaths (1 after thoracopic lobectomy and 1 after repair 
of ascending aortic aneurysm with concomitant aortic 
valve replacement and coronary artery bypass). The 
most common diagnostic complication was pneumo-
thorax as the majority of procedures were either bron-
choscopy or percutaneous lung biopsy. Of 10 patients 
with pneumothorax, 6 required a chest tube. Total 
procedure-related complication rate was 23/226 (10.1%). 
Surgery overall complication rate was 11/85 (12.9%) and 
Table 3. Additional Imaging in 500 Patients 














CT = computed tomography; MRI = magnetic resonance imaging; PET = posi-
tron emitted tomography.
Table 4. Invasive Interventions in 176 Patientsa 
(N = 226) 
Procedure Type No.






US-guided thyroid biopsy 23






Bone marrow biopsy 1
Surgeries 85
Thoracoscopic lobectomy 37
Thoracoscopic anatomic segmentectomy 11
Thoracoscopic wedge resection 7








Repair ascending aortic aneurysm with 
AVR/CAB
1
Aortic valve replacement 1
Thoracoscopic pleural biopsy 1
Mediastinal mass resection 1
Hepatectomy/Cholecystectomy 1
AVR = aortic valve replacement; CAB = coronary artery bypass; CT = computed 
tomography; US = ultrasound.
a Total number of procedures greater than 176 as some patients underwent 
multiple procedures.
Table 5. Cancers Diagnosed After Lung Cancer 
Screening of 3,402 Individuals (N = 111)
Lung Cancer
No. 
(n = 95) Other Cancer
No.  
(n = 16)
NSCLC stage I 60 Renal 4
NSCLC stage II 7 Breast 2
NSCLC stage III 9 Thyroid 1
NSCLC stage IV 8 Colon 1
Limited SCLC 4 Bile duct 1









NSCLC = non-small–cell lung cancer; SCLC = small cell lung cancer.
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30 day or surgery hospitalization mortality 2/84 (2.3%). 
Examining only thoracic surgery, the complication rate 
was 8/64 (12.5%) with 1/64 (1.5%) thoracic surgery 30 
day or surgery hospitalization mortality.
DISCUSSION
Given the endorsement of LCS by most patient advo-
cacy and professional organizations,2-5 health care 
delivery systems have been striving to implement LCS 
programs.8,15 Lung cancer screening provides for a stage 
shift to potentially curable lung cancer.1 Indeed, stage 
shift is the fundamental tenet of cancer screening. The 
utility of cancer screening in a well but at-risk popula-
tion, however, is predicated upon disease-specific sur-
vival improvement in the setting of minimal harm.16
The concern expressed regarding the generaliz-
ability of the outcomes reported by the National 
Lung Screening Trial1 was amplified by the American 
Academy of Family Physicians (AAFP), representing 
175,300 physicians and medical students nationwide.17 
The AAFP stated, “The NLST… favorable results were 
conducted in major medical centers with strict follow-up 
protocols for nodules, have not been replicated in a 
community setting… The harms of these follow-up 
interventions in a setting with a less strict follow-up 
protocol in the community is not known… Much of the 
success of this trial is based on the low mortality associ-
ated with surgical resection of tumors, which may not 
be reproducible in all settings.”9,10 As such, the AAFP 
issued: “Grade I recommendation: The AAFP concludes 
that the evidence is insufficient to recommend for or 
against screening for lung cancer with low-dose com-
puted tomography in persons at high risk for lung can-
cer based on age and smoking history.”9 Further, Huo et 
al18 used claims-based administrative data to create study 
cohorts with characteristics reflecting LCS eligibility 
and lung abnormalities on CT requiring interventions 
reported in the NLST (biopsy/cytology, bronchoscopy, 
thoracic surgery, other). They created a matched-
control cohort to model costs of care and reported 
overall complications in greater than 20% of interven-
tions, or double that reported by the NLST, specifically 
biopsy 18%, bronchoscopy 36%, and thoracic surgery 
51%. Thirteen percent of complications were major. 
Modeled complication costs were high. They posited 
their results to be representative of community practice 
outcomes, advised use of this information in LCS shared 
decision making, and cautioned that community-based 
LCS would not be equivalent to the NLST. Finally, 
Pham et al reported very low LCS utilization (1.9%) in 
those eligible,19 perhaps due to the above and/or to the 
logistics of implementing a LCS program.
To inform the broad medical trend of LCS imple-
mentation and specifically address the NLST general-
izability concerns outlined above, we evaluated LCS 
results in 3,402 people undergoing a total of 6,161 
LCSs within a community, non-NLST, non-university, 
metropolitan, large tertiary care system. Compared 
with NLST, our population was less white (86% vs 
91%), more female (50% vs 41%), older (age >65 years: 
56% vs 27%), and had more current smokers (60% vs 
48%). Our true positive or lung cancer diagnosis (95 
of 3,402 individuals), stage shift (79% non-small cell 
lung cancer diagnosed stage 1 or 2), intervention rate 
(14.6%), further evaluation after positive LCS domi-
nated by additional imaging vs procedures (CT was the 
most common additional imaging modality), procedure 
rate (6.6%), procedural adverse events (10.1%), surgical 
complications (12.9%), and 30-day or surgery-admission 
mortality (2.3%) are very similar to the NLST and the 
Veterans Health Administration reports.1,8
Care provided outside of study was not commented 
upon in the NLST. Although only 2% of our LCSs were 
performed outside PSJH, a substantial minority of our 
patients received indicated subsequent care outside 
of PSJH (additional imaging 31%, procedures 17%). 
This reality of community care is not reflected in our 
results, as our LCS coordinator tracked all clinical activ-
ity, providing 99.9% follow-up of the 3,402 screened 
individuals.
A possible weakness of our study nevertheless per-
tains to generalizability. Despite Portland PSJH being a 
community, non-university health system, our thoracic 
oncology program is staffed by chest specialists with 
local, regional, or national recognition. This expertise 
is reflected in our overall results, which we attribute to 
Table 6. Procedure-Related Adverse Events  
in 21 Patients (N = 23)
Adverse Events No.
Diagnostic procedure complicationsa 12
Pneumothorax 10
Unplanned ED admission post EBUS for 
hypoxemia
1
Post bronchoscopy pneumonia 1
Surgery complicationsb 11
Death 2
Reoperation for bleeding 2
Prolonged air leak 2
Postoperative respiratory failure 2
Chest wall hernia 1
Atrial fibrillation requiring intervention 1
Lung segment torsion requiring completion 
lobectomy
1
EBUS = endobronchial ultrasound; ED = emergency department.
a 11 patients.
b 10 patients.
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long-standing high clinical volume, multidisciplinary 
and specialized care,20 and is further manifest by our 
use of thoracoscopy for all pulmonary resections, and 
our low resection rate for benign disease, none of which 
suffered complications. Our LCS construct required 
resources, including medical leadership, and impor-
tantly, a full-time LCS coordinator. Without these, we 
could not have effectively followed and maintained 
timely interventions, or provided thorough results 
tracking, especially with care rendered outside of PSJH. 
Lack of availability of such resources could be a major 
limiting factor in the success of an LCS program.
Strengths of our study include the uniform applica-
tion of our programmatic and clinical practice with 
complete catchment of clinical data across a single 
large metropolitan health system within a large clini-
cal experience. We report 99.9% complete clinical 
follow-up. Additionally, our program complied with 
subsequently published program construct guide-
lines.6,7 Another strength was our high LCS adherence 
rate of 82% (Table 2), which was, however, somewhat 
lower than the 93-95% rate of the NLST. Finally, a 
hidden strength of this study is the rapid adoption 
and eager participation in LCS by the primary care 
clinician community in the Portland metropolitan area 
(Oregon). The primary care clinicians recognized in 
the NLST high-level clinical information and rapidly 
translated it into practice, prior even to their regional 
leadership‘s endorsement. The high rate of primary 
care clinician acceptance of our LCS program accounts 
for the high volume and upward trajectory (Figure 2) 
of patients evaluated. In fact, we did not market our 
LCS program due to the capacity limitation of having 
only a single program coordinator.
CONCLUSIONS
Low-dose computed tomography lung cancer screening 
can be done with low intervention and complication 
rates in a community non-university setting using, or 
more accurately stated, requiring a systematic multi-
disciplinary approach. This large cohort of screened 
patients demonstrates lung cancer diagnosis, stage shift, 
intervention frequency, and adverse event rate similar to 
the NLST. Our experience demonstrates that LCS can 
be done successfully and safely in a community setting.
To read or post commentaries in response to this article, see it 
online at http://www.AnnFamMed.org/content/18/3/243.
Key words: early cancer detection; lung cancer screening
Submitted October 11, 2019; accepted November 11, 2019.
Figure 2. Cumulative number of lung cancer screens, initial LCS only, and patients diagnosed with  
lung cancer.
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